Description:

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection; ODM derived from: https://clinicaltrials.gov/show/NCT01241760

Link:

https://clinicaltrials.gov/show/NCT01241760

Keywords:
Versions (1) ▾
  1. 6/9/20
Copyright Holder:
See clinicaltrials.gov
Uploaded on:

June 9, 2020

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Genotype 1 Chronic Hepatitis C NCT01241760

Details

Eligibility Genotype 1 Chronic Hepatitis C NCT01241760

Inclusion Criteria
patient has chronic hcv infection genotype 1 with hcv rna level > 1,000 iu/ml
patients should not have had any previous treatment for hepatitis c
patient must have documentation of a liver biopsy within 2 years before the screening visit or the patient must agree to have a biopsy performed within the screening period
patients with cirrhosis should have serum alpha-fetoprotein (afp) <= 50 ng/ml. if afp > 50 ng/ml, absence of a mass must be demonstrated by ultrasound within the screening period
a female patient of childbearing potential and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of birth control from screening until 6 months (female patient) or 7 months (male patient) after the last dose of rbv.
Exclusion Criteria
patient is infected or co-infected with hcv of another genotype than genotype 1 and/or patient is infected with more than one genotype subtype
patient has a pre-existing psychiatric condition
patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis c
patient has human immunodeficiency virus (hiv) or hepatitis b virus (hbv) co-infection
patient has active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma).
Back to the top of the page